
MODELING HYPOTHESES AND RECOMMENDATIONS
DDI Risk Analysis Project - med-ml
Generated: 2025-12-02 18:53:25
================================================================================

DATASET SUMMARY
--------------------------------------------------------------------------------
Total Patients: 25
Total DDI Pairs: 1219
Clusters Identified: 2

⚠️  IMPORTANT: Current dataset size (N=25) is too small for robust 
predictive modeling. Minimum recommended: 100-200 patients. These hypotheses are 
directional insights to be validated with larger dataset.

KEY FINDINGS AND HYPOTHESES
--------------------------------------------------------------------------------

1. AGE IS A PREDICTOR OF DDI RISK
   - Age-Risk Correlation: 0.392
   - Elderly (65+) Risk Factor: 4.90x higher than non-elderly
   - Mean Risk - Elderly: 108.55
   - Mean Risk - Non-Elderly: 22.14

   MODELING RECOMMENDATION:
   - Include Age as continuous feature
   - Include IsElderly binary flag (65+ threshold)
   - Consider age-stratified models or age interaction terms
   - Elderly patients may need separate risk scoring algorithm

2. POLYPHARMACY DRIVES DDI RISK
   - Polypharmacy Risk Factor: 137.91x higher than non-polypharmacy
   - Mean Risk - Polypharmacy: 114.92
   - Mean Risk - Non-Polypharmacy: 0.83

   MODELING RECOMMENDATION:
   - unique_medications is critical feature
   - Consider polynomial terms (medications²) for non-linear relationship
   - medication_diversity may capture additional risk beyond count
   - Polypharmacy threshold (5+ meds) is clinically validated

3. CLUSTERS ARE CLINICALLY DISTINCT
   - Number of clusters: 2
   - Clusters show significant differences in DDI risk (ANOVA p < 0.05)

   MODELING RECOMMENDATION:
   - Use cluster labels as features in predictive models
   - Consider cluster-specific models (ensemble approach)
   - Clusters can guide feature engineering (e.g., "elderly_high_complexity" flag)
   - Patient subgroups may need different intervention thresholds

4. MODERATE SEVERITY DDIs DOMINATE
   - Primary focus for clinical interventions
   - More prevalent than high-severity in current cohort

   MODELING RECOMMENDATION:
   - Severity should be weighted in risk scoring (High=3, Moderate=2, Low=1)
   - Consider separate models for severity prediction
   - Moderate DDIs may be more preventable than low severity

5. FEATURE CORRELATIONS INFORM MODEL DESIGN
   - Strong correlation between ddi_pair_count and total_ddi_risk_score
   - Age correlates with medication count and DDI risk

   MODELING RECOMMENDATION:
   - Check for multicollinearity before final model
   - May need to select subset of highly correlated features
   - Consider PCA or feature selection techniques

RECOMMENDED MODELING APPROACHES
--------------------------------------------------------------------------------

APPROACH 1: Binary Classification - High DDI Risk Prediction
  Target Variable: is_high_ddi_risk (1 if any moderate+ DDI, else 0)
  Use Case: Screening patients for medication review
  Algorithms: Logistic Regression (interpretable), Random Forest, XGBoost
  Evaluation: Precision-Recall (imbalanced classes), AUC-ROC

APPROACH 2: Regression - DDI Risk Score Prediction
  Target Variable: total_ddi_risk_score (continuous)
  Use Case: Quantifying risk magnitude for prioritization
  Algorithms: Linear Regression, Ridge/Lasso, Gradient Boosting
  Evaluation: MAE, RMSE, R²

APPROACH 3: Multi-Class Classification - Risk Stratification
  Target Variable: Risk Level (Low / Moderate / High)
  Use Case: Triaging patients to appropriate intervention levels
  Algorithms: Multi-class Logistic, Random Forest, Neural Network
  Evaluation: Multi-class F1, Confusion Matrix

APPROACH 4: Cluster-Based Ensemble
  Strategy: Train separate models for each cluster, combine predictions
  Use Case: Personalized risk assessment by patient subgroup
  Benefit: Captures cluster-specific patterns

DATA REQUIREMENTS FOR MODELING
--------------------------------------------------------------------------------

CURRENT STATUS: 25 patients - INSUFFICIENT for production models

MINIMUM REQUIREMENTS:
  - Development/Testing: 100-200 patients
  - Production Models: 500-1000 patients
  - Deep Learning: 5000+ patients

RECOMMENDED NEXT STEPS:
  1. Expand CDWWork database with additional synthetic patients
  2. Integrate PhysioNet or real VA data when available
  3. Implement stratified train/test/validation splits (70/15/15)
  4. Use k-fold cross-validation on training set
  5. Stratify by cluster to maintain distribution

VALIDATION STRATEGY
--------------------------------------------------------------------------------

TRAIN/TEST SPLIT:
  - Stratified by cluster (maintain cluster proportions)
  - Stratified by target variable (maintain class balance)
  - Time-based if temporal data available (train on older, test on newer)

CROSS-VALIDATION:
  - 5-fold or 10-fold stratified CV on training set
  - Use for hyperparameter tuning and model selection
  - Report mean ± std across folds

EVALUATION METRICS:
  - Primary: F1-score (balanced precision and recall)
  - Secondary: AUC-ROC, AUC-PR, Sensitivity, Specificity
  - For imbalanced data: Precision-Recall curve more informative than ROC
  - Clinical focus: Minimize false negatives (missing high-risk patients)

FEATURE ENGINEERING RECOMMENDATIONS
--------------------------------------------------------------------------------

KEEP AS-IS:
  - Age, unique_medications, ddi_pair_count (strong predictors)
  - Cluster labels (capture patient subgroup patterns)
  - Severity counts and total_ddi_risk_score

CONSIDER ADDING:
  - Age groups (binned: <50, 50-64, 65-79, 80+)
  - Medication count squared (non-linear relationship)
  - Age × Polypharmacy interaction term
  - Specific high-risk drug flags (Warfarin, etc.)
  - Temporal features (medication start recency)

CONSIDER REMOVING:
  - Highly correlated features (check VIF > 10)
  - Features with no variance across patients
  - Derived flags that are linear combinations of other features

CLINICAL DEPLOYMENT CONSIDERATIONS
--------------------------------------------------------------------------------

INTERPRETABILITY:
  - Healthcare requires explainable predictions
  - Use SHAP values or LIME for model explanations
  - Simple models (logistic regression, decision trees) easier to validate
  - Provide feature contributions for each prediction

INTEGRATION POINTS:
  - Pre-prescription screening ("Will adding Drug X create DDI?")
  - Periodic risk scoring (monthly batch jobs)
  - Real-time alerts in EHR at prescribing workflow
  - Care coordination flags for multi-system patients

ETHICAL CONSIDERATIONS:
  - Ensure model doesn't discriminate by age/gender
  - Validate across different patient subgroups
  - Regular retraining as clinical guidelines evolve
  - Human-in-the-loop for final decisions

CONCLUSION
--------------------------------------------------------------------------------

The clustering and analysis phases have identified clear patterns in DDI risk:
  ✓ Age and polypharmacy are primary risk factors
  ✓ Distinct patient clusters exist with different intervention needs
  ✓ Moderate-severity DDIs are the focus for clinical action
  ✓ Features are well-engineered and ready for modeling

Next Steps:
  1. Expand dataset to minimum 100 patients before modeling
  2. Implement train/test splits with stratification
  3. Start with simple baseline (logistic regression)
  4. Iterate with ensemble methods (Random Forest, XGBoost)
  5. Evaluate clinical validity with domain experts

Generated by: 06_analysis.ipynb
Date: 2025-12-02
